Bimatoprost
Glaucoma · Rx
RxGlaucomaGlaucoma Pga Turquoise cap
| Strength | 0.01% (ophthalmic) |
|---|---|
| Typical quantity | 2.5-5 mL bottle (generic available); Durysta is a separate office-placed implant |
| Cash cost / month | Low · ~$0-20 |
| Drug class | Prostaglandin analog (prostamide) |
| Mechanism of action | Prostamide analog; enhances both trabecular and uveoscleral outflow. Among the most potent IOP-lowering agents. |
| Indication / reason for use | Open-angle glaucoma and ocular hypertension. Durary biodegradable implant provides months of IOP control from a single intracameral administration. |
| Usual adult dosing | 1 drop once daily in the evening. |
| Preservative | BAK 0.02% (0.01% formulation) |
| Contact lenses | Remove lenses; reinsert after 15 minutes. |
| Common / important adverse effects | Conjunctival hyperemia (more than latanoprost), lash growth, iris and periocular pigmentation, periorbitopathy, macular edema (caution in aphakia/pseudophakia). |
| Contraindications & cautions | As for the PGA class. |
| Pregnancy / lactation | Avoid where possible. |
| Pregnancy category (older labels) | No letter category on the current label. From DailyMed labels, checked Nov 2026. |
| Trade names | Lumigan 0.01%, Latisse 0.03% (cosmetic), Durysta (implant) |
| Practice notes | Higher hyperemia rates than latanoprost can limit tolerability; the 0.03% strength was withdrawn from glaucoma use for this reason. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.